CMR Surgical raises largest ever MedTech private financing round worldwide to help bring Versius to hospitals around the world

Versius in operating theatre with surgical team

CMR Surgical, the Cambridge-based, global surgical robotics business, today announces that it has raised $600 million (£425 million) in a Series D financing. 

The round was led by SoftBank Vision Fund and co-led by Ally Bridge Group and will support the Company’s mission to make keyhole surgery accessible to more people worldwide. The funds will be used to increase the global commercialisation of Versius®, CMR’s next-generation surgical robotic system, and further develop its digital ecosystem.

CMR works with surgeons and hospitals to provide an optimal tool to make robotic keyhole surgery universally accessible and affordable. Versius’ size, portability and versatility have made it very popular with hospitals and surgeons around the world. As part of CMR’s ongoing international expansion, Versius has been successfully launched in multiple geographies worldwide including across Europe, Australia, India and the Middle East. Global demand for CMR’s surgical robot continues to grow with significant further momentum anticipated.

The Series D secures the financing to fully execute CMR’s strategy to rapidly accelerate its geographical expansion and builds upon the framework the Company has established to grow a long-term independent global business. The new funds also support the continued development of the system’s digital framework, including new technological developments such as Versius Connect, an app for surgeons using the Versius surgical robotic system.

The Cambridge Norwich Tech Corridor is at the forefront of a new era for life sciences and medtech as healthcare changes to meet the needs of our growing and ageing population.

The two major economics of the Tech Corridor are working at the exciting intersection of food and pharmaceuticals. Many of the 3,000 researchers working at Norwich Research Park are dedicated to developing new techniques in areas such as gut health, plant health and synthetic biology. This research expertise, coupled with the region’s strengths in agri-food and agri-tech, means the Tech Corridor is already playing a key role shaping the future of food.

In Cambridge, the fast-growing Biomedical Campus at Addenbrooke’s Hospital, home to world-leading businesses as well as institutes such as the MRC Molecular Biology Lab and the Cancer Research Cambridge Institute, complements the established hives of activity at Babraham Research Campus, Granta Park and the Wellcome Genome Campus. Life sciences is responsible for more than half of scientific R&D carried out in the city.

Clockwise from top, The Quadram Institute, University of East Anglia, EMBL-EBI and West Suffolk College's new STEM Innovation Centre

The advent of personalised medicine, where treatments are tailored to individual patients, means a new wave of medical devices for diagnosis and monitoring are about to hit clinics. And the engineering power of the Tech Corridor, with advanced manufacturing clusters in areas such as Thetford and Haverhill, mean it is the perfect place to bring your new product to life.

Want to find out more?

You can download our brochure, the Life Science Opportunity, which contains detailed information, maps and statistics about life science in the Tech Corridor.

For more information about how the Tech Corridor team can help your life science business, or if you are thinking of moving to the Tech Corridor, get in touch.